Polio and Post-Polio Syndrome

By Sieglinde W. Alexander November 27, 2023

Post-Polio Syndrome Revisited

Post-Polio Syndrome (PPS) is a neurological condition characterized by the recurrence or worsening of weakness, fatigue, and other motor symptoms decades after recovery from acute paralytic poliomyelitis. PPS is estimated to affect approximately 25–40% of polio survivors. Some of its clinical features can resemble motor neuron diseases (MNDs), including amyotrophic lateral sclerosis (ALS), because both conditions can involve progressive motor neuron dysfunction. However, PPS and ALS are distinct disorders with different clinical histories and pathological features.

Poliovirus Persistence and PPS

Poliovirus is a small RNA virus belonging to the Picornaviridae family. Unlike certain DNA viruses, such as herpesviruses, poliovirus does not integrate into human DNA or establish a classical latent infection. Therefore, the concept of a dormant poliovirus becoming reactivated decades later is not considered the primary explanation for PPS.

Nevertheless, several observations have raised questions about long-term poliovirus persistence. Rare individuals with immune deficiencies can develop chronic poliovirus infection, actively replicating and shedding virus for years without developing new neurological disease. Prolonged shedding lasting more than two decades has been documented in exceptional cases.

In addition, some studies of PPS patients have reported poliovirus RNA sequences, viral proteins, or continued immune responses in cerebrospinal fluid and other tissues decades after the initial infection. These findings remain controversial and may represent mutated or defective viral material rather than intact, infectious poliovirus. Consequently, detection of poliovirus-derived material should not be interpreted as evidence of a dormant virus undergoing conventional reactivation.

The prevailing explanation for PPS instead focuses on the long-term deterioration of motor units that survived the original infection. Following acute poliomyelitis, surviving motor neurons compensate for neuronal loss by forming enlarged motor units and supplying additional muscle fibers. After decades of increased metabolic and functional demand, these compensatory motor units may progressively deteriorate, resulting in renewed weakness, fatigue, and reduced endurance.

Diagnosis

There is currently no single laboratory test or biomarker that confirms PPS. Diagnosis is primarily clinical and requires a history of previous paralytic poliomyelitis, a prolonged period of neurological stability, and the later development of new or progressive symptoms. Other neurological, muscular, orthopedic, metabolic, and systemic disorders that could explain the symptoms must also be excluded.

Poliovirus Structure

Poliovirus consists of a single-stranded RNA genome enclosed within a protein capsid. The capsid contains four principal structural proteins—VP1, VP2, VP3, and VP4—which are important for viral structure, cell entry, and interactions with the host immune system. VP1, VP2, and VP3 are predominantly exposed on the viral surface, whereas VP4 is located internally.

Case Perspective

Herein, we describe a case of PPS in a 68-year-old man with a remote history of poliomyelitis involving the bulbar region and cervical spinal cord. The case is considered in the context of the relevant literature, with particular attention to the clinical and histopathological features that distinguish PPS from ALS. The comparison highlights the importance of previous poliomyelitis, patterns of motor neuron injury, and pathological findings when evaluating late-onset progressive weakness in polio survivors.

The poliovirus, which causes poliomyelitis (polio), is a small RNA virus belonging to the Picornaviridae family.

The virus is composed of an RNA genome enclosed in a protein shell called a capsid. The capsid is made up of four primary structural proteins, which are essential for the virus's ability to infect cells and are the target of the immune response. These proteins are:

VP1:What does VP1 do?
The VP1 protein is responsible for initiating the process of infecting a cell by binding to sialic acids in glycans, including some gangliosides, on the cell surface. Canonically, VP1 interacts specifically with α(2,3)-linked and α(2,6)-linked sialic acids. This protein is involved in the attachment of the virus to host cells. It interacts with the poliovirus receptor (PVR) on the surface of host cells, facilitating the virus's entry.
VP2:What is VP2 protein?
VP2 Whey Isolate is a pure isolated whey protein scientifically proven to be over 600% more effective for supporting muscle growth than other proteins. Pure Whey Peptide Isolates • Hydrolyzed Whey Fractions • “Bio-Active” Peptide Isolates • Highest Nitrogen Retention.VP2 along with VP1 and VP3, forms the outer surface of the viral capsid. It plays a role in the structural stability of the virus.
VP3: Similar to VP2, VP3 is a component of the outer surface of the viral capsid and contributes to the overall structure and stability of the virus. Which virus is VP3 protein isolated from?VP3, a Structural Protein of Infectious Pancreatic Necrosis Virus, Interacts with RNA-Dependent RNA Polymerase VP1 and with Double-Stranded RNA.
VP4: This protein is located on the inner surface of the capsid. It is believed to play a role in the release of viral RNA into the host cell after the virus has entered.
VP4 is an unglycosylated protein of the outer layer of the capsid of rotavirus. It forms spikes that project from the outer layer of mature virions, which is mainly constituted by glycoprotein VP7.

When the poliovirus infects a person, the immune system responds by producing antibodies against these capsid proteins. These antibodies can neutralize the virus, preventing it from infecting cells, which is the basis for immunity against polio. The inactivated polio vaccine (IPV) and oral polio vaccine (OPV) work by stimulating the body to produce these antibodies, providing protection against future poliovirus infections.

In the context of polio and post-polio syndrome, the relevant antibodies are primarily directed against the antigens of the poliovirus itself. Poliovirus, the causative agent of poliomyelitis, is a small RNA virus that comes in three serotypes (type 1, type 2, and type 3), each with its own specific antigens. The immune response to these antigens is crucial for both the resolution of the initial infection and long-term immunity.

Protein Antibodies Against Poliovirus Antigens:
- Neutralizing Antibodies: These antibodies are specific to the surface proteins of the poliovirus. Each of the three serotypes of the poliovirus has unique capsid proteins against which these neutralizing antibodies are formed. They are critical for preventing the virus from infecting cells and are the primary target of polio vaccines.
- IgM and IgG Antibodies: The immune system produces IgM antibodies as a first response to a poliovirus infection, which are later replaced by IgG antibodies for long-term immunity. These antibodies are directed against the proteins of the poliovirus.
Antibodies in Post-Polio Syndrome:
- In the case of post-polio syndrome (PPS), there is no direct association with specific antibodies against poliovirus proteins. PPS is a condition that affects polio survivors years after the initial infection, characterized by muscle weakness, fatigue, and pain. It is not caused by a persistent or reactivated virus but is believed to result from the long-term effects of the initial infection on motor neurons.
- Research into PPS does not typically focus on antibodies against the poliovirus, as the syndrome is not associated with an active infection. Instead, research might look at broader immune system responses or neurodegenerative processes.

In summary, the antibodies associated with poliovirus antigens are directed against specific proteins that make up the virus's outer capsid. These antibodies play a central role in protective immunity against polio by recognizing and neutralizing the virus before it can infect host cells. In contrast, post-polio syndrome (PPS) is not believed to result from an ongoing infection or persistent immune response to poliovirus antigens; therefore, the presence of specific anti-poliovirus antibodies is not considered a defining feature of PPS.

The most important antibodies in protection against poliovirus are neutralizing antibodies, which target the virus's surface capsid proteins. Poliovirus exists as three distinct serotypes, each possessing unique capsid protein structures that stimulate the production of serotype-specific neutralizing antibodies. These antibodies prevent the virus from attaching to and entering susceptible cells and represent the primary immune mechanism induced by polio vaccines.

During an acute poliovirus infection, the immune system initially produces immunoglobulin M (IgM) antibodies as part of the early immune response. As immunity matures, immunoglobulin G (IgG) antibodies are generated and persist long-term, providing durable immune protection and immunological memory. Both IgM and IgG antibodies are directed against poliovirus proteins, particularly the capsid antigens, and contribute to the body's defense against future poliovirus exposure.

Search This Blog

Q and A: about health and research